Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

HLA Typing and Tumor Neoantigen Identification for a Phase I/II Study of Autologous T-Cell Receptor-Engineered T Cells (TCR-T) Reactive Against Cancer-specific Mutations in Subjects With Solid Tumors

NCT05124743 is registered in ClinicalTrials.gov with Alaunos Therapeutics as lead sponsor.

NCT NCT05124743
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05124743 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
HLA Typing and Tumor Neoantigen Identification for a Phase I/II Study of Autologous T-Cell Receptor-Engineered T Cells (TCR-T) Reactive Against Cancer-specific Mutations in Subjects With Solid Tumors
Lead sponsor
Alaunos Therapeutics
Phase
Observational
Overall status
Terminated
Start date
September 24, 2021
Completion date
August 14, 2023
Enrollment
19 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cholangiocarcinoma, colo-rectal cancer, endometrial cancer, non-small cell lung cancer, ovarian cancer, pancreas cancer